NS-2028

TargetMol
Product Code: TAR-T16344
Supplier: TargetMol
CodeSizePrice
TAR-T16344-1mg1mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16344-2mg2mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16344-5mg5mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16344-1mL1 mL * 10 mM (in DMSO)£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16344-10mg10mg£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16344-25mg25mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16344-50mg50mg£667.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16344-100mg100mg£914.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor (IC50: 30 nM and 200 nM for basal and NO-stimulated enzyme activity). It is commonly used in the research of nitric oxide signaling pathways. NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase (IC50: 17 nM and 20 nM). NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells (IC50: 30 nM). NS-2028 inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM). NS-2028 decreases vascular endothelial growth factor-induced angiogenesis and permeability.
CAS:
204326-43-2
Formula:
C9H5BrN2O3
Molecular Weight:
269.054
Pathway:
; GPCR/G Protein
Purity:
0.9944
SMILES:
Brc1ccc2OCc3noc(=O)n3-c2c1
Target:
Guanylate cyclase

References

1. Olesen SP, et al. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309. 2. Morbidelli L, et al. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R824-32.